MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

Search

Fulgent Genetics Inc

Closed

SectorHealthcare

17.28 2.37

Overview

Share price change

24h

Current

Min

16.41

Max

17.49

Key metrics

By Trading Economics

Income

9.3M

-6.2M

Sales

4.5M

76M

EPS

0.04

Profit margin

-8.122

Employees

1,313

EBITDA

7.1M

-9.9M

Recommendations

By TipRanks

Recommendations

Neutral

12 Months Forecast

+6.51% upside

Dividends

By Dow Jones

Next Earnings

2 May 2025

Market Stats

By TradingEconomics

Market Cap

11M

523M

Previous open

14.91

Previous close

17.28

News Sentiment

By Acuity

50%

50%

163 / 386 Healthcare

Technical Score

By Trading Central

Confidence

Bearish Evidence

Fulgent Genetics Inc Chart

Past performance is not a reliable indicator of future results.

Related News

31 Mar 2025, 22:45 UTC

Top News

Intel's New CEO Plots Turnaround; 'We Need to Improve'

31 Mar 2025, 23:54 UTC

Market Talk

Nikkei May Rise After Monday's Selloff -- Market Talk

31 Mar 2025, 23:44 UTC

Market Talk

Gold Edges Higher Amid Prospects of Broader, Higher U.S. Tariffs -- Market Talk

31 Mar 2025, 23:15 UTC

Market Talk

Tower Shares Ease After Bain Capital Exit -- Market Talk

31 Mar 2025, 23:15 UTC

Market Talk

Global Equities Roundup: Market Talk

31 Mar 2025, 22:33 UTC

Top News

Trump Administration Targets Harvard With Review of $9 Billion in Federal Funding -- Update

31 Mar 2025, 22:28 UTC

Earnings

China Vanke: Weak China Real-Estate Market Weighed on Results >000002.SZ

31 Mar 2025, 22:28 UTC

Earnings

China Vanke 2024 Loss CNY49.48B Vs. Net CNY12.16B >000002.SZ

31 Mar 2025, 22:28 UTC

Earnings

China Vanke 2024 Rev CNY343.18B Vs. CNY465.74B >000002.SZ

31 Mar 2025, 22:28 UTC

Earnings

China Vanke Swings to Loss for 2024 >000002.SZ

31 Mar 2025, 21:47 UTC

Top News

Intel's New CEO Says Turnaround 'Won't Be Easy' -- Barrons.com

31 Mar 2025, 21:44 UTC

Top News

Trump Administration Targets Harvard With Review of $9 Billion in Federal Funding -- WSJ

31 Mar 2025, 21:21 UTC

Market Talk

Intel Has 'A Lot of Hard Work Ahead' in Turnaround, CEO Says -- Market Talk

31 Mar 2025, 21:18 UTC

Top News

Copper Is 2025's Hottest Commodity -- Update

31 Mar 2025, 21:09 UTC

Top News

Senate Aims to Advance Trump Tax Agenda While Postponing Spending-Cut Fight -- Update

31 Mar 2025, 21:02 UTC

Earnings

Freeport-McMoRan Sees 1Q Gold Sales 100,000 Ounces Below Previous Guidance of 225,000 Ounces >FCX

31 Mar 2025, 21:01 UTC

Earnings

Freeport-McMoRan Backs 1Q Consolidated Copper Sales of 850M Pounds >FCX

31 Mar 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

31 Mar 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

31 Mar 2025, 20:37 UTC

Top News

A Wild Quarter for U.S. Stocks Sends Investors Abroad -- 3rd Update

31 Mar 2025, 20:17 UTC

Top News

Dow Bounced Back After Tariff Concerns Hit Global Markets -- WSJ

31 Mar 2025, 20:13 UTC

Top News

A Wild Quarter for U.S. Stocks Sends Investors Abroad -- 2nd Update

31 Mar 2025, 20:03 UTC

Top News

A Wild Quarter for U.S. Stocks Sends Investors Abroad -- Update

31 Mar 2025, 19:09 UTC

Market Talk

Oil At 5-Week High as Trump Makes More Sanction Threats -- Market Talk

31 Mar 2025, 18:56 UTC

Market Talk

U.S. Natural Gas Gains With Help From Weather -- Market Talk

31 Mar 2025, 18:54 UTC

Market Talk

Canadian Banks' Fundamentals to Support Credit Ratings Near Term -- Market Talk

31 Mar 2025, 18:40 UTC

Market Talk

Walmart's Low Income Consumer Appears Increasingly Strained -- Market Talk

31 Mar 2025, 18:34 UTC

Market Talk

Ball, Crown Won't Be Materially Hurt if Soda Kicked Off Food Stamps -- Market Talk

31 Mar 2025, 18:28 UTC

Market Talk

Gold Climbs to Close Out Quarter -- Market Talk

31 Mar 2025, 18:03 UTC

Top News

Dow Edges Higher, Tariff Concerns Drag Down Global Markets -- WSJ

Peer Comparison

Price change

Fulgent Genetics Inc Forecast

Price Target

By TipRanks

6.51% upside

12 Months Forecast

Average 18 USD  6.51%

High 20 USD

Low 16 USD

Based on 2 Wall Street analysts offering 12 month price targets forFulgent Genetics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

2 ratings

0

Buy

2

Hold

0

Sell

Technical Score

By Trading Central

16.87 / 17.13Support & Resistance

Short Term

Bearish Evidence

Intermediate Term

Weak Bullish Evidence

Long Term

No Evidence

Sentiment

By Acuity

163 / 386 Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Fulgent Genetics Inc

Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in El Monte, California.